文献速递血栓与止血

艾多沙班延长治疗活动性癌症相关静脉血栓栓塞:Hokusai-VTE Cancer研究事后分析

Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
PubMed 文献 · J Thromb Haemost · 2019-07-25

该事后分析聚焦Hokusai-VTE Cancer试验6至12个月随访期,比较艾多沙班与达肝素延长抗凝的疗效与安全性。结果显示,6至12个月期间主要复合终点(复发性VTE或大出血)在艾多沙班组为2.4%,达肝素组为2.2%(未校正HR 1.05;95%CI 0.36-3.05)。结论认为,活动性癌症患者延长抗凝超过6个月时复发性VTE或大出血发生率相对较低,口服艾多沙班延长治疗似乎与皮下达肝素同样有效且安全。

要点

  • 6至12个月主要复合终点:艾多沙班组2.4% vs 达肝素组2.2%(未校正HR 1.05;95%CI 0.36-3.05)。
  • 复发性VTE:艾多沙班组0.7% vs 达肝素组1.1%;大出血:艾多沙班组1.7% vs 达肝素组1.1%。
  • 活动性癌症患者延长抗凝超过6个月时,复发性VTE或大出血发生率相对较低。

核心结论

  • 活动性癌症患者接受超过6个月的延长抗凝治疗时,复发性VTE或大出血发生率相对较低。
  • 口服艾多沙班延长治疗似乎与皮下达肝素同样有效且安全。

研究设计与样本

  • Hokusai VTE Cancer试验的事后分析,比较艾多沙班与达肝素治疗活动性癌症患者的VTE。
  • 分析聚焦6至12个月随访期;522例随机至艾多沙班,524例随机至达肝素。
  • 艾多沙班组294例(56%)和达肝素组273例(52%)接受治疗超过6个月,中位治疗持续时间分别为318天和211天。

主要发现

  • 6至12个月研究治疗期间,主要复合终点(复发性VTE或大出血)在艾多沙班组发生7例(2.4%),达肝素组6例(2.2%)(未校正HR 1.05;95%CI 0.36-3.05)。
  • 复发性VTE在艾多沙班组发生2例(0.7%),达肝素组3例(1.1%)。
  • 大出血在艾多沙班组发生5例(1.7%),达肝素组3例(1.1%)。

临床怎么用

  • 对于活动性癌症合并VTE患者,可考虑延长抗凝治疗超过6个月。
  • 口服艾多沙班可作为皮下达肝素之外的延长治疗选择。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence. Therefore, continued anticoagulant therapy beyond the initial 6 months is suggested in this patient population, but evidence supporting this approach is limited. METHODS: The Hokusai VTE Cancer trial compared edoxaban with dalteparin for VTE treatment in patients with active cancer. This post hoc analysis focused on the follow-up period from 6 to 12 months. The primary outcome was the composite of adjudicated first recurrent VTE or major bleeding. Secondary outcomes included recurrent VTE, major bleeding, and clinically relevant bleeding. RESULTS: Of the 522 and 524 patients randomized to edoxaban or dalteparin, 294 (56%) received edoxaban and 273 (52%) received dalteparin for more than 6 months (median duration of 318 and 211 days, respectively). Between 6 and 12 months, the primary outcome during study treatment occurred in seven patients (2.4%) in the edoxaban group and six patients (2.2%) in the dalteparin group (unadjusted hazard ratio 1.05; 95% confidence interval, 0.36-3.05). Recurrent VTE occurred in two patients (0.7%) in the edoxaban group and in three patients (1.1%) in the dalteparin group, whereas major bleeding occurred in 5 (1.7%) and three patients (1.1%), respectively. CONCLUSIONS: The rates of recurrent VTE or major bleeding are relatively low among patients with active cancer receiving extended anticoagulant therapy beyond 6 months. Extended treatment with oral edoxaban appears as effective and safe as subcutaneous dalteparin.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Di Nisio M, van Es N, Carrier M, et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019. PMID: 31271705. doi:10.1111/jth.14561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。